The FDA’s approval was based on data from the EXPLORER-HCM trial, which showed that mavacamten was superior to a placebo for treating obstructive HCM and associated with no significant long-term, treatment-related adverse events.

The new analysis, presented during Heart Rhythm 2022, focused on patients treated at a high-volume facility during the COVID-19 pandemic. 

New research, presented at Heart Rhythm 2022, found a 96% percent freedom from reoccurrence of atrial fibrillation in patients treated with high power vs. standard power radiofrequency ablation.

“I think he was the most brilliant person I’ve ever met," one long-time colleague said. 

Heart Rhythm 2022, held from April 28 to May 1 in San Francisco, included a wide range of studies presented by some of the industry's leading specialists. 

The FDA and Medtronic warn some Heartware Ventricular Assist Device (HVAD) systems have a defect that may cause pump thrombosis.

New data from the STROKE AF clinical trial shows large and small vessel ischemic stroke patients who receive short-term or intermittent monitoring with Holter and 30-day external monitors had fewer AFib episodes detected that continuous implantable cardiac monitors.

The results of a study published in Radiology: Cardiothoracic Imaging call into question the value of initiating aspirin therapy in certain instances.

Staff who participated in a hybrid remote schedule reported better work/life balance and increased productivity, according to a new survey.

Radiologists have developed an abdominal x-ray protocol that quantifies patient “thickness” to yield images of high quality while reducing radiation dose by 80%.